Gastrointestinal stromal tumor | Tumor

CURE’s gastrointestinal stromal tumor page features the latest cancer news and updates on gastrointestinal stromal tumors Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in the gastrointestinal stromal tumor.

GIST Location Predicts Tumor Mutation Profile and Drug Sensitivity

August 13th 2021, 9:00pm


The location of gastrointestinal stromal tumors in the stomach predicts the mutation profile and drug sensitivity, which can provide direction for treatment decisions and selective genomic testing.

Drug-Resistant GIST: Identifying Patients and Finding Solutions

July 14th 2021, 9:00pm


Gastrointestinal stromal tumors that are SDH deficient are less likely to respond to TKI treatment. A researcher discusses the exploration of a new drug that can work in this patient population.

Rare Cancers: Collaboration Moves the Field Forward

July 13th 2021, 3:00pm


Patients, clinicians and researchers should work together to find new therapies for rare cancers, one expert says.

How Do Clinical Trials Work? Cancer Expert Explains It All

July 1st 2021, 3:00pm


Will patients be given a placebo? Are clinical trials safe? An expert answers these questions and more.

When Treatment Options Run Out, Consider a Higher Drug Dose in GIST

June 29th 2021, 1:00pm


In patients with advanced gastrointestinal stromal tumors, a dose escalation of Qinlock after recommended treatment with the agent may be the best next step, answering for the lack of a next approved agent after Qinlock.

Early Evidence Shows Gleevec-Xpovio Combo May Benefit Patients With Rare Form of Advanced Gastrointestinal Cancer

June 25th 2021, 1:00pm


The combination of Gleevec and Xpovio demonstrated some promising results in a small group of patients with a rare form of advanced gastrointestinal cancer whose disease had failed to respond to prior first-line treatment with Gleevec.

Dose Escalation of Qinlock Shows Benefit in Patients With Advanced GIST

June 22nd 2021, 1:00pm


The findings open up the door for a fourth-line treatment option in patients with advanced gastrointestinal stromal tumors with disease progression.

Novel Drug Significantly Improves Survival in Rare Gastrointestinal Cancer

June 9th 2021, 1:00pm


Treatment with the study drug was associated with a doubling of a survival outcome in patients with advanced gastrointestinal stromal tumor, compared to placebo.

Higher Dose of Qinlock Improves Survival in Patients with Heavily Pretreated Advanced GIST

June 7th 2021, 4:00pm


Twice-daily treatment with Qinlock following disease progression after treatment with fourth-line therapy in patients with advanced gastrointestinal stromal tumor was associated with extended survival outcomes.

Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation

April 16th 2021, 9:00pm


Ayvakit demonstrated more durable survival outcomes in patients with unresectable/metastatic platelet-derived growth factor receptor A D842V-mutant gastrointestinal stromal tumors than tyrosine kinase inhibitors.